Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) CFO Sells 4,290 Shares of Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) CFO Kyle Piskel sold 4,290 shares of the business’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $18.00, for a total transaction of $77,220.00. Following the transaction, the chief financial officer owned 216,637 shares in the company, valued at approximately $3,899,466. This represents a 1.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Kyle Piskel also recently made the following trade(s):

• On Friday, November 28th, Kyle Piskel sold 162,820 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $19.50, for a total transaction of $3,174,990.00.
• On Monday, November 17th, Kyle Piskel sold 238 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.05, for a total transaction of $3,343.90.

Adaptive Biotechnologies Trading Down 0.2%

Adaptive Biotechnologies stock traded down $0.03 during mid-day trading on Wednesday, hitting $18.04. 1,865,999 shares of the company’s stock were exchanged, compared to its average volume of 1,982,211. Adaptive Biotechnologies Corporation has a 1-year low of $6.26 and a 1-year high of $20.76. The stock has a 50 day moving average of $16.50 and a two-hundred day moving average of $14.44. The stock has a market cap of $2.75 billion, a P/E ratio of -33.41 and a beta of 2.18.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.01. Adaptive Biotechnologies had a negative return on equity of 58.40% and a negative net margin of 31.50%.The company had revenue of $93.97 million during the quarter, compared to the consensus estimate of $58.76 million. During the same quarter in the prior year, the company posted ($0.22) EPS. The firm’s revenue was up 102.4% on a year-over-year basis. As a group, research analysts predict that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ADPT has been the topic of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Wednesday, October 8th. Morgan Stanley initiated coverage on shares of Adaptive Biotechnologies in a research note on Monday, December 1st. They issued an “equal weight” rating and a $21.00 price objective on the stock. Guggenheim initiated coverage on shares of Adaptive Biotechnologies in a research note on Tuesday, September 30th. They issued a “buy” rating and a $20.00 price objective on the stock. Wall Street Zen upgraded shares of Adaptive Biotechnologies from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Finally, BTIG Research raised their price target on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $17.11.

Institutional Trading of Adaptive Biotechnologies

A number of large investors have recently bought and sold shares of ADPT. Sound Income Strategies LLC acquired a new stake in shares of Adaptive Biotechnologies in the 3rd quarter valued at $30,000. Smartleaf Asset Management LLC lifted its holdings in Adaptive Biotechnologies by 593.5% during the 3rd quarter. Smartleaf Asset Management LLC now owns 3,939 shares of the company’s stock valued at $59,000 after purchasing an additional 3,371 shares during the last quarter. Caxton Associates LLP acquired a new position in Adaptive Biotechnologies in the first quarter valued at about $93,000. Quadrant Capital Group LLC acquired a new position in Adaptive Biotechnologies in the third quarter valued at about $133,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in Adaptive Biotechnologies during the second quarter worth about $134,000. 99.17% of the stock is currently owned by institutional investors.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.